Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)

NCT04676724 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT04676724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04676724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIb Multi-Center, Randomised, Open Label Study to Assess the Efficacy and Safety of Sequential Treatment With GSK3228836 Followed by Pegylated Interferon Alpha 2a in Participants With Chronic Hepatitis B Virus (B-Together)
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
January 28, 2021
Completion date
February 17, 2023
Enrollment
108 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b